Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT03292861
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Autologous Stem Cell Transplant for Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Aaron Etra
- Target Recruit Count
- 50
- Registration Number
- NCT03219359
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 192
- Registration Number
- NCT03190733
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2017-05-31
- Target Recruit Count
- 30
- Registration Number
- NCT03171831
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Kinetic Study of CD8+ CMV-specific Cellular Immunity in Renal Transplant Patients After Receiving Thymoglobulin
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2021-07-20
- Target Recruit Count
- 150
- Registration Number
- NCT03147183
- Locations
- 🇪🇸
Hosìtal Universitario Reina Sofia, Córdoba, Spain
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2017-04-19
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 38
- Registration Number
- NCT03121014
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
- First Posted Date
- 2017-04-19
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT03121001
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Hospital Geral de Fortaleza
- Target Recruit Count
- 200
- Registration Number
- NCT03088280
- Locations
- 🇧🇷
Transplant ward of the Hospital do Fortaleza, Fortaleza, Ceará, Brazil
Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 100
- Registration Number
- NCT03006419
- Locations
- 🇲🇽
Umae Hospital Especialidades 14 Adolfo Ruiz Cortines, Veracruz, Mexico
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Monica Bhatia
- Target Recruit Count
- 24
- Registration Number
- NCT02867800
- Locations
- 🇺🇸
North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.